TY - JOUR
T1 - Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex
AU - Beran, M.
AU - Andersson, B.
AU - Eksborg, S.
AU - Ehrsson, H.
N1 - Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 1979/3
Y1 - 1979/3
N2 - The sensitivity of normal and acute nonlymphocytic leukemia-derived granulocytic stem cells (colony-forming units in culture, CFUc), exposed to daunorubicin, daunorubicinol, or daunorubicin-DNA complex in short-term suspension culture in vitro was studied. Normal CFUc were found to be considerably more sensitive to daunorubicin than to daunorubicinol. Killing of normal marrow CFUc by daunorubicin was an exponential function of the dose within the time and dose range tested. The C50 varied between 100 and 230 ng/ml medium, LD37 between 53 and 79 ng/ml medium. The response of CFUc to daunorubicin-DNA complex was exponential with somewhat larger individual variations (C50=100-330 ng/ml, LD37=46-878 ng/ml). The in vitro sensitivity of leukemia-patient derived CFUc to daunorubicin showed a greater variation (C50=127-454 ng/ml, LD37=74-640 ng/ml) than that of normal-control derived CFUc. In comparative studies with the leukemia-derived CFUc, daunorubicin-DNA complex was more or as effective as the free drug in killing CFUc derived from some patients, but in killing the CFUc derived from other patients was far less effective than the free drug. The results indicate greater individual variations in the response of leukemia-derived than normal CFUc both to daunorubicin and to daunorubicin-DNA complex in vitro. The therapeutic relevance of the results is discussed.
AB - The sensitivity of normal and acute nonlymphocytic leukemia-derived granulocytic stem cells (colony-forming units in culture, CFUc), exposed to daunorubicin, daunorubicinol, or daunorubicin-DNA complex in short-term suspension culture in vitro was studied. Normal CFUc were found to be considerably more sensitive to daunorubicin than to daunorubicinol. Killing of normal marrow CFUc by daunorubicin was an exponential function of the dose within the time and dose range tested. The C50 varied between 100 and 230 ng/ml medium, LD37 between 53 and 79 ng/ml medium. The response of CFUc to daunorubicin-DNA complex was exponential with somewhat larger individual variations (C50=100-330 ng/ml, LD37=46-878 ng/ml). The in vitro sensitivity of leukemia-patient derived CFUc to daunorubicin showed a greater variation (C50=127-454 ng/ml, LD37=74-640 ng/ml) than that of normal-control derived CFUc. In comparative studies with the leukemia-derived CFUc, daunorubicin-DNA complex was more or as effective as the free drug in killing CFUc derived from some patients, but in killing the CFUc derived from other patients was far less effective than the free drug. The results indicate greater individual variations in the response of leukemia-derived than normal CFUc both to daunorubicin and to daunorubicin-DNA complex in vitro. The therapeutic relevance of the results is discussed.
UR - http://www.scopus.com/inward/record.url?scp=0018760809&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018760809&partnerID=8YFLogxK
U2 - 10.1007/BF00253100
DO - 10.1007/BF00253100
M3 - Article
C2 - 498414
AN - SCOPUS:0018760809
SN - 0344-5704
VL - 2
SP - 19
EP - 24
JO - Cancer chemotherapy and pharmacology
JF - Cancer chemotherapy and pharmacology
IS - 1
ER -